Nabriva Therapeutics (FRA:NTY) EV-to-Revenue : 0.03 (As of May. 26, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Nabriva Therapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Nabriva Therapeutics's enterprise value is €0.75 Mil. Nabriva Therapeutics's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was €28.19 Mil. Therefore, Nabriva Therapeutics's EV-to-Revenue for today is 0.03.

The historical rank and industry rank for Nabriva Therapeutics's EV-to-Revenue or its related term are showing as below:

FRA:NTY' s EV-to-Revenue Range Over the Past 10 Years
Min: -3.5 Med: 0.12 Max: 137.44
Current: -0.06

During the past 10 years, the highest EV-to-Revenue of Nabriva Therapeutics was 137.44. The lowest was -3.50. And the median was 0.12.

FRA:NTY's EV-to-Revenue is ranked better than
92.97% of 1039 companies
in the Biotechnology industry
Industry Median: 8.18 vs FRA:NTY: -0.06

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-26), Nabriva Therapeutics's stock price is €0.665. Nabriva Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was €9.37. Therefore, Nabriva Therapeutics's PS Ratio for today is 0.07.

Nabriva Therapeutics EV-to-Revenue Historical Data

The historical data trend for Nabriva Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nabriva Therapeutics EV-to-Revenue Chart

Nabriva Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EV-to-Revenue

Get a 7-Day Free Trial

2.98

9.44

6.06

-0.21

-0.03

Nabriva Therapeutics Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
EV-to-Revenue	Get a 7-Day Free Trial															-0.03	-0.07	-0.03	0.12	0.11

Competitive Comparison of Nabriva Therapeutics's EV-to-Revenue

For the Biotechnology subindustry, Nabriva Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nabriva Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nabriva Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Nabriva Therapeutics's EV-to-Revenue falls into.

Nabriva Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Nabriva Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	0.753	/	28.191
	=	0.03

Nabriva Therapeutics's current Enterprise Value is €0.75 Mil.
Nabriva Therapeutics's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €28.19 Mil.

Nabriva Therapeutics (FRA:NTY) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Nabriva Therapeutics's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	0.665	/	9.371
	=	0.07

Nabriva Therapeutics's share price for today is €0.665.
Nabriva Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €9.37.

Nabriva Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Nabriva Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Nabriva Therapeutics (FRA:NTY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nabriva Therapeutics PLC (FRA:NTY) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

NBRVF:USA

Address

Alexandra House, Office 225/227, The Sweepstakes, Dublin, IRL, 4

Website

https://www.nabriva.com

Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company has developed a product candidate, XENLETA, a semi-synthetic pleuromutilin antibiotic that is the first in its class for oral and IV administration in humans. XENLETA is designed to inhibit the synthesis of a specific protein on the bacterial ribosome. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections. The firm has commercial rights to two approved products, SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO.

Nabriva Therapeutics (FRA:NTY) Headlines

No Headlines